Current phase I/II study showed that CXCR4 inhibitor Plerixafor was well tolerated as an adjunct to chemoirradiation in newly diagnosed glioblastoma patients and reduced tumor local recurrences by inhibiting postirradiation tumor revascularization (177). This evidence concerns the gene CXCR4 and glioblastoma.